Online Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 577 - Estimands: Some Perspectives from an FDA Working Group
Type: Topic Contributed
Date/Time: Thursday, August 6, 2020 : 3:00 PM to 4:50 PM
Sponsor: Biopharmaceutical Section
Abstract #312235
Title: Estimands in Clinical Endpoint Bioequivalence Trials
Author(s): Wanjie Sun*
Companies: FDA
Keywords: estimand; principal stratification; intercurrent event; equivalence

In bioequivalence, biosimilar and non-inferiority (NI) studies, intent-to-treat (ITT) analysis tends to make the two treatments look similar, thereby is generally considered anti-conservative. The Per Protocol (PP) analysis based on completers and compliers is more able to reflect treatment differences and is usually preferred in equivalence or NI assessments. However, missing data and non-compliance are post-randomization intercurrent events and may introduce selection bias to the study conclusion. Therefore, the usually used naïve PP estimand may not be causal. In this work, we propose a principal stratification causal framework and causal estimands to test equivalence, which was one of the five approaches recommended by the ICH E9 (R1) addendum to address intercurrent events. We also propose a tipping point sensitivity analysis to evaluate the robustness of the current PP estimator in testing equivalence when the sensitivity parameters deviate from the three identified conditions, but stay within a clinically meaningful range. Our work can be applied to comparative biosimilar clinical trials and non-inferiority trials.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2020 program